Elsevier

Annals of Oncology

Volume 32, Supplement 5, September 2021, Pages S1044-S1045
Annals of Oncology

1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

https://doi.org/10.1016/j.annonc.2021.08.1489Get rights and content
Under an Elsevier user license
open archive

Cited by (0)